BTG1 expression was restored after 5-aza-2′-deoxycytidine treatment in gastric, breast, and ovarian cancer cells, indicating that BTG1 promoter methylation accounted for its down-regulated expression in cancer cells (15, 20, 21). The gene discussed is BTG1; the disease is ovarian cancer.